Author: Tsuchiya, Atsunori; Takeuchi, Suguru; Iwasawa, Takahiro; Kumagai, Masaru; Sato, Takeki; Motegi, Satoko; Ishii, Yui; Koseki, Youhei; Tomiyoshi, Kei; Natsui, Kazuki; Takeda, Nobutaka; Yoshida, Yuki; Yamazaki, Fusako; Kojima, Yuichi; Watanabe, Yusuke; Kimura, Naruhiro; Tominaga, Kentaro; Kamimura, Hiroteru; Takamura, Masaaki; Terai, Shuji
Title: Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases Cord-id: fcqtstpk Document date: 2020_6_22
ID: fcqtstpk
Snippet: The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) and the ensuing worldwide pandemic. The spread of the virus has had global effects such as activity restriction, economic stagnation, and collapse of healthcare infrastructure. Severe SARS-CoV-2 infection induces a cytokine storm, leading to acute respiratory distress syndrome (ARDS) and multiple organ failure, which are very serious health conditions a
Document: The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) and the ensuing worldwide pandemic. The spread of the virus has had global effects such as activity restriction, economic stagnation, and collapse of healthcare infrastructure. Severe SARS-CoV-2 infection induces a cytokine storm, leading to acute respiratory distress syndrome (ARDS) and multiple organ failure, which are very serious health conditions and must be mitigated or resolved as soon as possible. Mesenchymal stem cells (MSCs) and their exosomes can affect immune cells by inducing anti-inflammatory macrophages, regulatory T and B cells, and regulatory dendritic cells, and can inactivate T cells. Hence, they are potential candidate agents for treatment of severe cases of COVID-19. In this review, we report the background of severe cases of COVID-19, basic aspects and mechanisms of action of MSCs and their exosomes, and discuss basic and clinical studies based on MSCs and exosomes for influenza-induced ARDS. Finally, we report the potential of MSC and exosome therapy in severe cases of COVID-19 in recently initiated or planned clinical trials of MSCs (33 trials) and exosomes (1 trial) registered in 13 countries on ClinicalTrials.gov.
Search related documents:
Co phrase search for related documents- acute ali lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ali lung injury and lung migrate: 1
- acute ali lung injury model and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute ards respiratory distress syndrome and additional file: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
- acute ards respiratory distress syndrome and low immunogenicity: 1, 2, 3
- acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lung disease chronic disease: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lung migrate: 1
- acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute gvhd host versus graft disease and lung injury: 1, 2
- acute gvhd host versus graft disease and lymphocyte count: 1
- acute toxicity and lung disease: 1, 2, 3, 4, 5, 6
- acute toxicity and lung injury: 1, 2, 3, 4, 5
- additional file and lung disease chronic disease: 1, 2
- additional file and lung image: 1, 2
- additional file and lung injury: 1, 2, 3, 4, 5, 6
- additional file and lymphocyte count: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date